+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

HIV Drugs - Market Analysis, Trends, and Forecasts

  • ID: 1227763
  • Report
  • 167 Pages
  • Global Industry Analysts, Inc
1 of 3

FEATURED COMPANIES

  • Abbvie
  • Astrazeneca Plc
  • Cipla
  • Daiichi Sankyo
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences
  • MORE
The HIV Drugs market worldwide is projected to grow by US$6.3 Billion, driven by a compounded growth of 3.6%. Multi-Class Combination Drugs, one of the segments analyzed and sized in this study, displays the potential to grow at over 4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$10.4 Billion by the year 2025, Multi-Class Combination Drugs will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 2.8% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$229.7 Million to the region's size and clout in the next 5 to 6 years. Over US$185.9 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, Multi-Class Combination Drugs will reach a market size of US$549.9 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 5.7% over the next couple of years and add approximately US$1.8 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:
  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Emcure Pharmaceuticals Pvt., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Hetero Drugs Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbvie
  • Astrazeneca Plc
  • Cipla
  • Daiichi Sankyo
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences
  • MORE

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Global Competitor Market Shares

HIV Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: HIV Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 2: HIV Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017

TABLE 3: HIV Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025

TABLE 4: Multi-Class Combination Drugs (Medication Class) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 5: Multi-Class Combination Drugs (Medication Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 6: Multi-Class Combination Drugs (Medication Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 7: Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (Medication Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025

TABLE 8: Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (Medication Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017

TABLE 9: Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (Medication Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

TABLE 10: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (Medication Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025

TABLE 11: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (Medication Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017

TABLE 12: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (Medication Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

TABLE 13: Protease Inhibitors (PIs) (Medication Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025

TABLE 14: Protease Inhibitors (PIs) (Medication Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017

TABLE 15: Protease Inhibitors (PIs) (Medication Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025

TABLE 16: Fusion Inhibitors (FI) (Medication Class) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 17: Fusion Inhibitors (FI) (Medication Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 18: Fusion Inhibitors (FI) (Medication Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

TABLE 19: Entry Inhibitors (Medication Class) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025

TABLE 20: Entry Inhibitors (Medication Class) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017

TABLE 21: Entry Inhibitors (Medication Class) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025

TABLE 22: HIV Integrase Stand Transfer Inhibitors (Medication Class) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025

TABLE 23: HIV Integrase Stand Transfer Inhibitors (Medication Class) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017

TABLE 24: HIV Integrase Stand Transfer Inhibitors (Medication Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US HIV Drugs Market Share (in %) by Company: 2019 & 2025

TABLE 25: United States HIV Drugs Market Estimates and Projections in US$ Million by Medication Class: 2018 to 2025

TABLE 26: HIV Drugs Market in the United States by Medication Class: A Historic Review in US$ Million for 2009-2017

TABLE 27: United States HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

CANADA

TABLE 28: Canadian HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018 to 2025

TABLE 29: Canadian HIV Drugs Historic Market Review by Medication Class in US$ Million: 2009-2017

TABLE 30: HIV Drugs Market in Canada: Percentage Share Breakdown of Sales by Medication Class for 2009, 2019, and 2025

JAPAN

TABLE 31: Japanese Market for HIV Drugs: Annual Sales Estimates and Projections in US$ Million by Medication Class for the Period 2018-2025

TABLE 32: HIV Drugs Market in Japan: Historic Sales Analysis in US$ Million by Medication Class for the Period 2009-2017

TABLE 33: Japanese HIV Drugs Market Share Analysis by Medication Class: 2009 VS 2019 VS 2025

CHINA

TABLE 34: Chinese HIV Drugs Market Growth Prospects in US$ Million by Medication Class for the Period 2018-2025

TABLE 35: HIV Drugs Historic Market Analysis in China in US$ Million by Medication Class: 2009-2017

TABLE 36: Chinese HIV Drugs Market by Medication Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

EUROPE

Market Facts & Figures

European HIV Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025

TABLE 37: European HIV Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025

TABLE 38: HIV Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017

TABLE 39: European HIV Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025

TABLE 40: European HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018-2025

TABLE 41: HIV Drugs Market in Europe in US$ Million by Medication Class: A Historic Review for the Period 2009-2017

TABLE 42: European HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

FRANCE

TABLE 43: HIV Drugs Market in France by Medication Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 44: French HIV Drugs Historic Market Scenario in US$ Million by Medication Class: 2009-2017

TABLE 45: French HIV Drugs Market Share Analysis by Medication Class: 2009 VS 2019 VS 2025

GERMANY

TABLE 46: HIV Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Medication Class for the Period 2018-2025

TABLE 47: German HIV Drugs Historic Market Analysis in US$ Million by Medication Class: 2009-2017

TABLE 48: German HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

ITALY

TABLE 49: Italian HIV Drugs Market Growth Prospects in US$ Million by Medication Class for the Period 2018-2025

TABLE 50: HIV Drugs Historic Market Analysis in Italy in US$ Million by Medication Class: 2009-2017

TABLE 51: Italian HIV Drugs Market by Medication Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED KINGDOM

TABLE 52: United Kingdom Market for HIV Drugs: Annual Sales Estimates and Projections in US$ Million by Medication Class for the Period 2018-2025

TABLE 53: HIV Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Medication Class for the Period 2009-2017

TABLE 54: United Kingdom HIV Drugs Market Share Analysis by Medication Class: 2009 VS 2019 VS 2025

SPAIN

TABLE 55: Spanish HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018 to 2025

TABLE 56: Spanish HIV Drugs Historic Market Review by Medication Class in US$ Million: 2009-2017

TABLE 57: HIV Drugs Market in Spain: Percentage Share Breakdown of Sales by Medication Class for 2009, 2019, and 2025

RUSSIA

TABLE 58: Russian HIV Drugs Market Estimates and Projections in US$ Million by Medication Class: 2018 to 2025

TABLE 59: HIV Drugs Market in Russia by Medication Class: A Historic Review in US$ Million for 2009-2017

TABLE 60: Russian HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

REST OF EUROPE

TABLE 61: Rest of Europe HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018-2025

TABLE 62: HIV Drugs Market in Rest of Europe in US$ Million by Medication Class: A Historic Review for the Period 2009-2017

TABLE 63: Rest of Europe HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

ASIA-PACIFIC

TABLE 64: Asia-Pacific HIV Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 65: HIV Drugs Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017

TABLE 66: Asia-Pacific HIV Drugs Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025

TABLE 67: HIV Drugs Market in Asia-Pacific by Medication Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 68: Asia-Pacific HIV Drugs Historic Market Scenario in US$ Million by Medication Class: 2009-2017

TABLE 69: Asia-Pacific HIV Drugs Market Share Analysis by Medication Class: 2009 VS 2019 VS 2025

AUSTRALIA

TABLE 70: HIV Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Medication Class for the Period 2018-2025

TABLE 71: Australian HIV Drugs Historic Market Analysis in US$ Million by Medication Class: 2009-2017

TABLE 72: Australian HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

INDIA

TABLE 73: Indian HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018 to 2025

TABLE 74: Indian HIV Drugs Historic Market Review by Medication Class in US$ Million: 2009-2017

TABLE 75: HIV Drugs Market in India: Percentage Share Breakdown of Sales by Medication Class for 2009, 2019, and 2025

SOUTH KOREA

TABLE 76: HIV Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Medication Class for the Period 2018-2025

TABLE 77: South Korean HIV Drugs Historic Market Analysis in US$ Million by Medication Class: 2009-2017

TABLE 78: HIV Drugs Market Share Distribution in South Korea by Medication Class: 2009 VS 2019 VS 2025

REST OF ASIA-PACIFIC

TABLE 79: Rest of Asia-Pacific Market for HIV Drugs: Annual Sales Estimates and Projections in US$ Million by Medication Class for the Period 2018-2025

TABLE 80: HIV Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Medication Class for the Period 2009-2017

TABLE 81: Rest of Asia-Pacific HIV Drugs Market Share Analysis by Medication Class: 2009 VS 2019 VS 2025

LATIN AMERICA

TABLE 82: Latin American HIV Drugs Market Trends by Region/Country in US$ Million: 2018-2025

TABLE 83: HIV Drugs Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017

TABLE 84: Latin American HIV Drugs Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025

TABLE 85: Latin American HIV Drugs Market Growth Prospects in US$ Million by Medication Class for the Period 2018-2025

TABLE 86: HIV Drugs Historic Market Analysis in Latin America in US$ Million by Medication Class: 2009-2017

TABLE 87: Latin American HIV Drugs Market by Medication Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

ARGENTINA

TABLE 88: Argentinean HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018-2025

TABLE 89: HIV Drugs Market in Argentina in US$ Million by Medication Class: A Historic Review for the Period 2009-2017

TABLE 90: Argentinean HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

BRAZIL

TABLE 91: HIV Drugs Market in Brazil by Medication Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 92: Brazilian HIV Drugs Historic Market Scenario in US$ Million by Medication Class: 2009-2017

TABLE 93: Brazilian HIV Drugs Market Share Analysis by Medication Class: 2009 VS 2019 VS 2025

MEXICO

TABLE 94: HIV Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Medication Class for the Period 2018-2025

TABLE 95: Mexican HIV Drugs Historic Market Analysis in US$ Million by Medication Class: 2009-2017

TABLE 96: Mexican HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

REST OF LATIN AMERICA

TABLE 97: Rest of Latin America HIV Drugs Market Estimates and Projections in US$ Million by Medication Class: 2018 to 2025

TABLE 98: HIV Drugs Market in Rest of Latin America by Medication Class: A Historic Review in US$ Million for 2009-2017

TABLE 99: Rest of Latin America HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

MIDDLE EAST

TABLE 100: The Middle East HIV Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 101: HIV Drugs Market in the Middle East by Region/Country in US$ Million: 2009-2017

TABLE 102: The Middle East HIV Drugs Market Share Breakdown by Region/Country: 2009, 2019, and 2025

TABLE 103: The Middle East HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018 to 2025

TABLE 104: The Middle East HIV Drugs Historic Market by Medication Class in US$ Million: 2009-2017

TABLE 105: HIV Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Medication Class for 2009, 2019, and 2025

IRAN

TABLE 106: Iranian Market for HIV Drugs: Annual Sales Estimates and Projections in US$ Million by Medication Class for the Period 2018-2025

TABLE 107: HIV Drugs Market in Iran: Historic Sales Analysis in US$ Million by Medication Class for the Period 2009-2017

TABLE 108: Iranian HIV Drugs Market Share Analysis by Medication Class: 2009 VS 2019 VS 2025

ISRAEL

TABLE 109: Israeli HIV Drugs Market Estimates and Forecasts in US$ Million by Medication Class: 2018-2025

TABLE 110: HIV Drugs Market in Israel in US$ Million by Medication Class: A Historic Review for the Period 2009-2017

TABLE 111: Israeli HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

SAUDI ARABIA

TABLE 112: Saudi Arabian HIV Drugs Market Growth Prospects in US$ Million by Medication Class for the Period 2018-2025

TABLE 113: HIV Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Medication Class: 2009-2017

TABLE 114: Saudi Arabian HIV Drugs Market by Medication Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED ARAB EMIRATES

TABLE 115: HIV Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Medication Class for the Period 2018-2025

TABLE 116: United Arab Emirates HIV Drugs Historic Market Analysis in US$ Million by Medication Class: 2009-2017

TABLE 117: HIV Drugs Market Share Distribution in United Arab Emirates by Medication Class: 2009 VS 2019 VS 2025

REST OF MIDDLE EAST

TABLE 118: HIV Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Medication Class for the Period 2018-2025

TABLE 119: Rest of Middle East HIV Drugs Historic Market Analysis in US$ Million by Medication Class: 2009-2017

TABLE 120: Rest of Middle East HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

AFRICA

TABLE 121: African HIV Drugs Market Estimates and Projections in US$ Million by Medication Class: 2018 to 2025

TABLE 122: HIV Drugs Market in Africa by Medication Class: A Historic Review in US$ Million for 2009-2017

TABLE 123: African HIV Drugs Market Share Breakdown by Medication Class: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBVIE

ASTRAZENECA PLC

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

BRISTOL-MYERS SQUIBB COMPANY

CIPLA

DAIICHI SANKYO

EMCURE PHARMACEUTICALS PRIVATE LIMITED

F. HOFFMANN-LA ROCHE AG

GILEAD SCIENCES

JOHNSON & JOHNSON

MERCK & CO., INC.

TEVA PHARMACEUTICAL INDUSTRIES

VIIV HEALTHCARE

V. CURATED RESEARCH

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbvie
  • Astrazeneca Plc
  • Boehringer Ingelheim International GMBH
  • Bristol-Myers Squibb Company
  • Cipla
  • Daiichi Sankyo
  • Emcure Pharmaceuticals Private Limited
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries
  • Viiv Healthcare
Note: Product cover images may vary from those shown
Adroll
adroll